NASDAQ · Analyst Forecast

Lisata Therapeutics, Inc. (LSTA) Analyst Forecast

$1.06 NASDAQ: LSTA Market Cap $9.55M

Revenue and earnings estimates published by analysts covering Lisata Therapeutics, Inc. (LSTA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Lisata Therapeutics, Inc., analysts forecast revenue rising from $1.07T in 2024 to $45.00T in 2029; the average estimate for 2029 earnings per share is $0.00; 2 analysts contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2024	$1.07T	$1.07T	$1.07T	2
2025	$33.3B	$33.3B	$33.3B	1
2026	$134.7B	$134.7B	$134.7B	1
2027	$5.00T	$5.00T	$5.00T	1
2028	$7.20T	$7.20T	$7.20T	1
2029	$45.00T	$45.00T	$45.00T	1

Earnings per share forecast

Year	Low	Average	High	Analysts
2024	$-2.64	$-2.62	$-2.60	2
2025	$-2.33	$-2.33	$-2.33	1
2026	$-1.09	$-1.09	$-1.09	1
2027	$-1.16	$-1.16	$-1.16	1
2028	$-0.98	$-0.98	$-0.98	1
2029	$0.00	$0.00	$0.00	1

Lisata Therapeutics, Inc. (LSTA) forecast — frequently asked questions

What are analysts forecasting for Lisata Therapeutics, Inc.'s earnings?

The average analyst estimate for Lisata Therapeutics, Inc. (LSTA) earnings per share in 2029 is 0.00, with individual estimates between 0.00 and 0.00.

How much revenue is Lisata Therapeutics, Inc. expected to make?

Analysts forecast Lisata Therapeutics, Inc. (LSTA) revenue of $45.00T in 2029, based on 1 published estimates.

How many analysts cover LSTA?

2 analysts contribute estimates for Lisata Therapeutics, Inc. (LSTA). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.